Valley National Advisers’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Valley National Advisers’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-776	Closed	-$90K	–	1296
2023 Q3	$90K	Hold	776	–	–	0.02%	310
2023 Q2	$80K	Hold	776	–	–	0.01%	331
2023 Q1	$86K	Hold	776	–	–	0.02%	319
2022 Q4	$87K	Buy	776 +223	+40%	+$18.5K	0.02%	320
2022 Q3	$35K	Sell	553 -248	-31%	-$17.3K	0.01%	422
2022 Q2	$67K	Hold	801	–	–	0.01%	314
2022 Q1	$84K	Buy	801 +140	+21%	+$13.6K	0.02%	301
2021 Q4	$71K	Hold	661	–	–	0.01%	321
2021 Q3	$72K	Buy	661 +303	+85%	+$31.5K	0.01%	311
2021 Q2	$34K	Hold	358	–	–	0.01%	401
2021 Q1	$33K	Buy	358 +63	+21%	+$5.32K	0.01%	379
2020 Q4	$22K	Hold	295	–	–	﹤0.01%	419
2020 Q3	$23K	Buy	+295	New	+$20.3K	0.01%	386

Other funds holding HZNP

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

VWA

Valued Wealth Advisors Holladay, Utah $275M AUM 24.94% 1-Year Est. Return

FSWA

Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return

BCMLT

Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Valley National Advisers's HZNP Position: Q4 2023 in Review

Valley National Advisers sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 776 shares — an estimated $90K sold.

Valley National Advisers first reported a position in HZNP in Q3 2020 and held it in 13 quarters. The position peaked at $90K in Q3 2023. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

Valley National Advisers reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
Valley National Advisers sold 776 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $90K.
Valley National Advisers first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2020 and held it in 13 quarters.
Valley National Advisers's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $90K in Q3 2023.
6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Valley National Advisers's 13F filing for Q4 2023, filed 25 Jan 2024.